share_log

Truist Securities Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $7

Benzinga ·  Nov 8, 2023 09:51

Truist Securities analyst Gregory Fraser maintains Amneal Pharmaceuticals (NYSE:AMRX) with a Buy and raises the price target from $6 to $7.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment